Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen.

× No keyword cloud information.

19 in total

Review 1. Streptokinase--the drug of choice for thrombolytic therapy.

Authors: Adinarayana Kunamneni; Thaer Taleb Abed Abdelghani; Poluri Ellaiah
Journal: J Thromb Thrombolysis Date: 2007-02 Impact factor: 2.300

2. Specific isoforms of plasminogen in patients with prostate cancer.

Authors: D I Vodolazhsky; E F Shin; A Yu Golikov; T N Belova; D V Zimakov; E N Cherkasova; N V Boyko; M I Kogan; M B Chibichian; S A Moshkovsky; D G Matishov
Journal: Dokl Biol Sci Date: 2011-07-05

3. Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein.

Authors: J M Edelberg; J J Enghild; S V Pizzo; M Gonzalez-Gronow
Journal: J Clin Invest Date: 1990-07 Impact factor: 14.808

4. Plasminogen interacts with human platelets through two distinct mechanisms.

Authors: L A Miles; M H Ginsberg; J G White; E F Plow
Journal: J Clin Invest Date: 1986-06 Impact factor: 14.808

5. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.

Authors: S Müllertz
Journal: Biochem J Date: 1974-11 Impact factor: 3.857

10. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.

Authors: J Mimuro; S Kimura; N Aoki
Journal: J Clin Invest Date: 1986-03 Impact factor: 14.808

Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen.

Review 1. Streptokinase--the drug of choice for thrombolytic therapy.

2. Specific isoforms of plasminogen in patients with prostate cancer.

3. Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein.

4. Plasminogen interacts with human platelets through two distinct mechanisms.

5. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.

6. Genetic polymorphism of human plasminogen.

7. Analysis of the interactions between streptokinase domains and human plasminogen.

8. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.

9. Synthesis and catabolism of rabbit alpha 1-antitrypsins F and S.

10. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.